MeiraGTx Holdings PLC
NASDAQ:MGTX
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
MeiraGTx Holdings PLC
NASDAQ:MGTX
|
626.1m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
196.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
MeiraGTx Holdings PLC
Glance View
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 287 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1, which is for the treatment of grade two/three radiation-induced xerostomia; AAV-GAD, is for the treatment of Parkinson’s disease, and AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia (ACHM). The firm has six programs in clinical development, including Phase I/Il clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa and RPE65-Deficiency, and Phase I clinical trials for radiation-induced xerostomia (RIX), and a Parkinson’s program that has completed a Phase II trial with published data.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for MeiraGTx Holdings PLC is -615.3%, which is above its 3-year median of -895.7%.
Over the last 3 years, MeiraGTx Holdings PLC’s Net Margin has decreased from -265.6% to -615.3%. During this period, it reached a low of -1 969.3% on Sep 30, 2023 and a high of -265.6% on Aug 30, 2022.
